Creating value across our world of Food & Beverages to Pharmaceuticals Introducing the 3 business domains of the Kirin Group
Expanding the business domains based on fermentation and biotechnology
Since its founding in 1907, the Kirin Group has continued to grow for over 100 years.
Starting from the beer business, the company expanded into the Food & Beverages domain, and from the 1980s, fermentation and biotechnology have been used to expand into the Pharmaceuticals and Health Science domains. The Kirin Group is working to provide products and services that increase the quality of life for consumers in all of their life stages and at the same time solve the social issues.
Kirin Group brands spanning the globe
Since its founding, the Kirin Group has remained connected to consumers through products and services and is offering numerous brands in various regions and countries around the world.
In the Food & Beverages domain, the Kirin Group has expanded into overseas markets mainly in Asia and Oceania and is well-known and loved by many consumers.
Recently in the Health Science domain, highly functional products and services that utilize the group’s strengths have been developed.
Resolve key issues in business domains
Business domains and values provided
Social problems to be solved
Vision for each business
Food & Beverages domain
Form bonds between people and revitalize communities through our alcoholic beverages and soft drinks.
Contribute to well-being for consumers' daily life through Food and Beverages
|A Responsible Alcohol Producer||Dealing with alcohol-related problems||
Reform the profit structure by enhancing brands in existing businesses and exploring new businesses
|Health and well-being||Support for the prevention of non-communicable diseases|
|Community Engagement||Respect for human rights|
|The Environment||Overcoming climate change, Sustainable recycling of containers and packaging|
|Health Science domain Maintain health through Food and Beverages by preventing disease and suppressing its progression||Health and well-being||Support for maintaining immunity||
|The Environment||Overcoming climate change, Sustainable use of water resources|
|Pharmaceuticals domain Develop new drugs using advanced biotechnology. Restore health through personalized treatment and aftercare||Health and well-being||Fulfill unmet medical needs||
Accelerate growth ofhealth science businesses and establish a stable profit structure as a global specialty pharma company
|The Environment||Overcome climate change|
Form a new growth track and implement the Long-Term Vision KV2027
Under the Long-Term Management Vision “Kirin Group Vision 2027 (KV2027)” established in 2019, Kirin Group is aiming to become a global leader in CSV, creating value across the domains of Food & Beverages to Pharmaceuticals.
During the first three years of the Medium-Term Business Plan (2019-2021), key performance indicators of economic value was unachieved due to the significant impact imposed by the COVID-19 pandemic. As such, normalized operating profit recorded for 2021 was below the level seen in 2018.
However, Kirin Group is committed to maintaining its goal to achieve mid-single-digit growth in normalized operating profit CAGR by 2027 relative to 2018. In response to the ever-changing business environment, we will plan for dramatic growth in the Food & Beverages domain and the Pharmaceuticals domain. At the same time, we will expand the scale of the Health Science domain, an area which plays a role that is crucial for long-term growth.
Food & Beverages
Products and services that bring people together
Food & Beverages is the original business domain of Kirin Group and still is its foundational business domain. Although we were significantly affected by the pandemic, the Group will work to recover and achieve further growth.
In the alcoholic beverages business, the main markets where the Group operates, Japan and Australia, are both mature markets, so quantitative growth is not expected to be significant. To achieve sustainable growth, the Group needs to increase the proportion of products and services which offer higher levels of added value. The Group is implementing specific strategies to achieve this, such as by strengthening craft beer in both of those markets and in North America.
In the non-alcoholic beverages business, competition is becoming increasingly severe in the Japanese market. From a long-term perspective, the Group has been striving to increase the proportion of brands offering added value relating to health and well-being with the aim to reposition the non-alcoholic beverages business to play a larger role in the Health Science domain.
Our core targets of SDGs
Key non-ﬁnancial performance indicators(2024)
Increase in sales volume of non-alcoholic beverages
+17 % (compared to 2021)
Key ﬁnancial performance indicators(2027)
Food & Beverages domain:
Normalized operating profit margin
25 % or higher
- Sales revenue after liquor tax
Products and services that contribute to increasing quality of life
Through many years of research into natural ingredients, cells and microorganisms, the Kirin Group has succeeded in discovering numerous materials that contribute to health and well-being, such as Lactococcus lactis strain Plasma (LC-Plasma). The Health Science domain will utilize these unique materials to address the social issues of health and well-being.
While creating synergies between Kyowa Kirin and FANCL, the Kirin Group will establish a unique business model and aim to achieve a higher profit growth rate than the Food & Beverages and Pharmaceuticals domains.
Continuing to discover innovative new drugs
Kyowa Kirin, from the Pharmaceuticals domain, was created through a merger between Kyowa Hakko Kogyo and Kirin Pharma , which originated from Kirin Brewery’s pharmaceuticals division. Kyowa Kirin is a research and development style company that utilizes state of the art biotechnology centered on antibody technology. As one of Japan’s major life science companies, Kyowa Kirin will always pursue new possibilities and strive to contribute to the health and well-being of people around the world by creating new value.
In the 2021-2025 Medium-Term Business Plan, “Provide pharmaceuticals for unmet medical needs”, “Address patient-centric healthcare needs” and “Retain the trust of society” have been set forth as the three strategies, and the Pharmaceuticals domain is expected to drive the growth of the Kirin Group over the medium-term.
Our core targets of SDGs
Key non-ﬁnancial performance indicators (2024)
Number of countries / regions where Crysvita has launched
50 or more counties/regions (2025)
Key ﬁnancial performance indicators(2025)
CAGR 10 % or higher
Core Operating profit margin
25 % or higher
The Kirin appears as a prelude to joyous times to come
Kirin Group is working to solve a wide range of social issues around the world.The following introduces the "value creation" story from the perspective of several fields.